BG63711B1 - Фармацевтичен препарат, съдържащ протеиназен инхибитор и моноглицерид - Google Patents

Фармацевтичен препарат, съдържащ протеиназен инхибитор и моноглицерид Download PDF

Info

Publication number
BG63711B1
BG63711B1 BG102106A BG10210697A BG63711B1 BG 63711 B1 BG63711 B1 BG 63711B1 BG 102106 A BG102106 A BG 102106A BG 10210697 A BG10210697 A BG 10210697A BG 63711 B1 BG63711 B1 BG 63711B1
Authority
BG
Bulgaria
Prior art keywords
hydroxy
phenyl
amino
acid
butyl
Prior art date
Application number
BG102106A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102106A (en
Inventor
Anne BAILEY
Josephine FERDINANDO
Navnit Shah
Original Assignee
F. Hoffmann- La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/616,233 external-priority patent/US6008228A/en
Application filed by F. Hoffmann- La Roche Ag filed Critical F. Hoffmann- La Roche Ag
Publication of BG102106A publication Critical patent/BG102106A/xx
Publication of BG63711B1 publication Critical patent/BG63711B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BG102106A 1995-06-06 1997-12-05 Фармацевтичен препарат, съдържащ протеиназен инхибитор и моноглицерид BG63711B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46849395A 1995-06-06 1995-06-06
US08/616,233 US6008228A (en) 1995-06-06 1996-05-07 Pharmaceutical compositions containing proteinase inhibitors
PCT/EP1996/002431 WO1996039142A1 (en) 1995-06-06 1996-06-04 Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride

Publications (2)

Publication Number Publication Date
BG102106A BG102106A (en) 1998-08-31
BG63711B1 true BG63711B1 (bg) 2002-10-31

Family

ID=27042422

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102106A BG63711B1 (bg) 1995-06-06 1997-12-05 Фармацевтичен препарат, съдържащ протеиназен инхибитор и моноглицерид

Country Status (27)

Country Link
EP (1) EP0831826B1 (de)
JP (1) JP3238412B2 (de)
CN (1) CN1092960C (de)
AT (1) ATE226075T1 (de)
AU (1) AU709796B2 (de)
BG (1) BG63711B1 (de)
BR (1) BR9610842A (de)
CA (1) CA2224125C (de)
CY (1) CY2373B1 (de)
CZ (1) CZ292192B6 (de)
DE (1) DE69624354T2 (de)
DK (1) DK0831826T3 (de)
EA (1) EA001413B1 (de)
ES (1) ES2182996T3 (de)
HK (1) HK1010136A1 (de)
HU (1) HU223899B1 (de)
IL (1) IL122353A0 (de)
IS (1) IS2661B (de)
MX (1) MX9709193A (de)
NO (1) NO324531B1 (de)
NZ (1) NZ311646A (de)
OA (1) OA10546A (de)
PL (1) PL184820B1 (de)
PT (1) PT831826E (de)
SK (1) SK282121B6 (de)
TR (1) TR199701541T1 (de)
WO (1) WO1996039142A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2203648C2 (ru) 1997-07-29 2003-05-10 Фармация Энд Апджон Компани Самоэмульгирующаяся композиция для липофильных соединений
PT989851E (pt) 1997-07-29 2002-12-31 Upjohn Co Formulacao auto-emulsionante para compostos lipofilicos acidicos
CN1232244C (zh) * 1999-02-08 2005-12-21 阿尔萨公司 稳定的非水性单相粘性载体及采用该载体的制剂
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
BR0202252A (pt) 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DK2020990T3 (da) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2108705A1 (de) 2008-04-08 2009-10-14 Universität Duisburg-Essen Verfahren zur Analyse der epigenetischen Lage des HtrA1 Gens in einer biologischen Probe
JP5718925B2 (ja) 2009-09-28 2015-05-13 インターシア セラピューティクス，インコーポレイティド 実質的な定常状態薬物送達の迅速な確立及び／又は停止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

Also Published As

Publication number Publication date
JP3238412B2 (ja) 2001-12-17
PL184820B1 (pl) 2002-12-31
HUP9801905A2 (hu) 1999-05-28
SK282121B6 (sk) 2001-11-06
DK0831826T3 (da) 2003-02-03
WO1996039142A1 (en) 1996-12-12
EA001413B1 (ru) 2001-02-26
CA2224125A1 (en) 1996-12-12
AU6300496A (en) 1996-12-24
CY2373B1 (en) 2004-06-04
DE69624354T2 (de) 2003-06-05
CN1186434A (zh) 1998-07-01
EP0831826A1 (de) 1998-04-01
HU223899B1 (hu) 2005-03-29
ATE226075T1 (de) 2002-11-15
DE69624354D1 (de) 2002-11-21
HUP9801905A3 (en) 2001-04-28
HK1010136A1 (en) 1999-06-17
AU709796B2 (en) 1999-09-09
PL323860A1 (en) 1998-04-27
ES2182996T3 (es) 2003-03-16
NZ311646A (en) 2000-02-28
NO324531B1 (no) 2007-11-12
SK162797A3 (en) 1998-05-06
CZ380397A3 (cs) 1998-03-18
TR199701541T1 (xx) 1998-03-21
IS4627A (is) 1997-12-04
CA2224125C (en) 2004-09-28
IS2661B (is) 2010-08-15
NO975665D0 (no) 1997-12-05
OA10546A (en) 2002-05-29
JPH10507202A (ja) 1998-07-14
IL122353A0 (en) 1998-04-05
CZ292192B6 (cs) 2003-08-13
CN1092960C (zh) 2002-10-23
PT831826E (pt) 2003-02-28
BR9610842A (pt) 1999-07-13
NO975665L (no) 1998-02-05
EP0831826B1 (de) 2002-10-16
MX9709193A (es) 1998-03-31
BG102106A (en) 1998-08-31
EA199800023A1 (ru) 1998-08-27

Similar Documents

Publication Publication Date Title
AU709796B2 (en) Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
US6008228A (en) Pharmaceutical compositions containing proteinase inhibitors
PL179717B1 (pl) Kompozycja farmaceutyczna zawierajaca trudno rozpuszczalna substancje czynnaw kompozycji nosnikowej PL PL PL PL PL PL PL PL
JP2007291131A (ja) エイズを処置する方法におけるチトクロームｐ４５０により代謝される薬物の薬物動態を改善するためのリトナビル（ａｂｔ−５３８）の使用
JP2002500233A (ja) 抗−クリプトコッカルペプチド類
JPH10505324A (ja) レトロウイルスプロテアーゼインヒビターの組合せ
JP2012529523A (ja) Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
EP0431828B1 (de) Verbesserungen betreffend die Verabreichung pharmazeutischer Mittel
EP3827831A1 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von nichtalkoholischer steatohepatitis
ES2356986T3 (es) Agentes antitumorales.
KR20210081338A (ko) Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물
US20030229124A1 (en) Lipid peroxide-lowering compositions
NZ235914A (en) Immunosuppressant pharmaceutical composition
WO2005007191A1 (ja) 医薬組成物
CN113631161A (zh) 用于治疗癌症的口服施用的多西他赛和P-gp抑制剂的治疗组合
US6201009B1 (en) Absorption-enhancing composition for pantothenic acid derivative
US20230014055A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
JP2002241311A (ja) 界面活性剤を含む医薬組成物
WO1995021624A1 (fr) Preparation sous forme de solution a base d'une forte concentration d'aureobasidine
SK126998A3 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
PL203441B1 (pl) Kompozycja farmaceutyczna zawieraj aca rozpuszczony zwi azek hamuj acy proteaz e HIV
JPH07267875A (ja) オーレオバシジン類の高濃度溶液製剤
KR20000004919A (ko) Vx 478과 같은 hiv 프로테아제 억제제 및 비타민 e-tpgs와 같은 수용성 비타민 e 화합물을 포함하는 조성물